SCHEMBL9967690

SCHEMBL9967690

CC(C)c1ccc2nsnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 2/20 0.48
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
SCN4A P35499 1/20 0.46
MEN1 O00255 7/20 0.42
KMT2A Q03164 7/20 0.42
MAPT P10636 6/20 0.42
ALDH1A1 P00352 5/20 0.42
GAA P10253 5/20 0.42
POLB P06746 2/20 0.42
APAF1 O14727 2/20 0.42
TDP2 O95551 2/20 0.42
CASP3 P42574 2/20 0.42
BLM P54132 2/20 0.42
SENP8 Q96LD8 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
SENP6 Q9GZR1 2/20 0.42
CASP6 P55212 1/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17541594 0.83 PTPN11 (0.45) PTPN11NPC1RAB9ASMN1; SMN2SCN4A
SCHEMBL22627565 0.83 PTPN11 (0.45) PTPN11NPC1RAB9ASMN1; SMN2SCN4A
SCHEMBL17541537 0.83 PTPN11 (0.45) PTPN11NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL20509299 0.83 PTPN11 (0.50) PTPN11NPC1RAB9ASMN1; SMN2SCN4A
SCHEMBL20072428 0.80 ALDH1A1 (0.43) PTPN11SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL19966718 0.77 RAB9A (0.49) PTPN11NPC1RAB9ASMN1; SMN2SCN4A
SCHEMBL2706284 0.75 NPC1 (0.50) NPC1RAB9ASMN1; SMN2SCN4AMEN1
SCHEMBL12938128 0.75 NPC1 (0.50) NPC1RAB9ASMN1; SMN2SCN4AMEN1
SCHEMBL1619361 0.71 OGA (0.49) NPC1RAB9ASMN1; SMN2SCN4AMAPT
SCHEMBL22725525 0.71 NPC1 (0.47) NPC1RAB9ASMN1; SMN2SCN4AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
WO-2024137852-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-06-27 WO disclosed
WO-2024044757-A1 AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS Sanford Burnham Prebys Medical Discovery Institute (US) 2024-02-29 WO disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-01-18 US disclosed
US-20210300948-A1 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS Frequency Therapeutics, Inc. 2021-09-30 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
US-7989472-B2 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use MERCK SHARP & DOHME CORP. (US) 2011-08-02 US disclosed
US-20100286151-A1 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders BENTLEY JONATHAN 2010-11-11 US disclosed
US-20090209564-A1 Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use MERCK & CO., INC. 2009-08-20 US disclosed
US-20090209564-A1 Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use MERCK & CO., INC. 2009-08-20 US disclosed
US-20090192175-A1 INSECTICIDAL COMPOUNDS SYNGENTA CROP PROTECTION, INC. (US) 2009-07-30 US disclosed
US-20090042897-A1 Chemical Compounds GLAXO GROUP LIMITED (GB) 2009-02-12 US disclosed
US-20090005375-A1 ACETYL COENZYME A CARBOXYLASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-01 US disclosed
WO-2008121592-A2 ACETYL COENZYME A CARBOXYLASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-09 WO disclosed
EP-1947085-A1 Substituted indole sulfonamide compounds, their preparation and use as medicaments Laboratorios del Dr. Esteve S.A. (ES) 2008-07-23 EP disclosed
WO-2007042325-A1 ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 PTPN11 1306/4885NPC1 2447/4885RAB9A 3109/4885
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 PTPN11 94/4885NPC1 1821/4885RAB9A 650/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 PTPN11 4087/4885NPC1 72/4885RAB9A 2129/4885
US-11225469-B2 Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof PHGDH, PGD, PGK1 PTPN11 2156/4885NPC1 3992/4885RAB9A 1994/4885
US-20210300948-A1 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS MCL1, PROX1, MKI67 PTPN11 4046/4885NPC1 4230/4885RAB9A 3442/4885
US-20090209564-A1 Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use GCGR, GLP1R, GPR119 PTPN11 1039/4885NPC1 1918/4885RAB9A 3427/4885
US-20090005375-A1 ACETYL COENZYME A CARBOXYLASE INHIBITORS ACACA, ACACB, ACAT1 PTPN11 3999/4885NPC1 904/4885RAB9A 4576/4885
US-20090192175-A1 INSECTICIDAL COMPOUNDS ACHE, CHRM1, CYP1B1 PTPN11 4304/4885NPC1 684/4885RAB9A 172/4885
US-20090042897-A1 Chemical Compounds NPY5R, NPY1R, NPY2R PTPN11 432/4885NPC1 3083/4885RAB9A 1618/4885
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D PTPN11 59/4885NPC1 1886/4885RAB9A 455/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 PTPN11 4087/4885NPC1 72/4885RAB9A 2129/4885
US-20100286151-A1 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders NPY5R, NPY1R, NPY4R PTPN11 450/4885NPC1 1203/4885RAB9A 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.